Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

BUFFALO, N.Y., July 25, 2022 -- Athenex, Inc., , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and...

Related Keywords

China ,United States ,Ukraine ,American ,Daniel Lang ,Caileigh Dougherty ,American Society Of Clinical Oncology Journal ,Investor Relations Department ,Nasdaq ,Athenex Inc ,Metastatic Breast ,American Society ,Clinical Oncology Journal ,California San Francisco Comprehensive Cancer ,Kuur Therapeutics ,Nasdaq Global Market ,Investor Relations ,